- Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size
-
Bender L, Kurtz JE, Petit T, Pivot X
- KMID: 2511854
- J Breast Cancer.
- 2020 Dec;23(6):672-673.
- doi: 10.4048/jbc.2020.23.e62
-
- CITED
-
- Close
- SHARE
-
- Close
- Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer
-
Sabatier R, Diéras V, Pivot X, Brain E, Roché H, Extra JM, Monneur A, Provansal , Tarpin C, Bertucci F, Viens P, Zemmour C, Gonçalves A
- KMID: 2424795
- Cancer Res Treat.
- 2018 Oct;50(4):1226-1237.
- doi: 10.4143/crt.2017.446
PURPOSE: Eribulin is approved for advanced breast cancers refractory to anthracyclines and taxanes. Efficacy according to sensitivity to previous therapies has been poorly explored. MATERIALS AND METHODS: Safety data were collected... -
- CITED
-
- Close
- SHARE
-
- Close
